The North America Age Related Macular Degeneration (AMD) Market should witness market growth of 4.9% CAGR during the forecast period (2023-2030).
The most common cause of blindness in senior patients in developed nations is age-related macular degeneration (AMD). It is an eye condition that affects older people's eyes and leads to a progressive loss of the central vision needed for tasks like reading, driving, recognizing people, and examining color. As AMD worsens, many patients lose their ability to read, write, or distinguish between colors and details, which lowers their quality of life. Although the precise functional cause of AMD is not yet fully known, recent advancements in genetic technology have allowed for the identification of several variants that have been found to have distinctive relationships with the disease.
The center of vision becomes blurry as a result. A blood vessel growth abnormality could cause loss of eyesight. On rare occasions, it may be possible to identify abnormal new blood vessels developing from the choroid into the macula. The choroid (sclera), made up of a layer of blood vessels, is located between the retina and the outside, a solid coat of the eye. These abnormal blood vessels may leak blood or fluid, impairing the retina's ability to function.
As the first biosimilar to Lucentis (ranibizumab injection), the U.S. Food and Drug Administration approved Byooviz (ranibizumab-nuna) for the treatment of several eye diseases and conditions, including neovascular (wet) age-related macular degeneration (AMD), a major cause of vision loss and blindness among Americans aged 65 and beyond. Additionally, byooviz is authorized for the treatment of myopic choroidal neovascularization, a risky eye condition brought about by myopia (nearsightedness), as well as macular edema (fluid buildup) following retinal vein occlusion (blockage of veins in the retina). According to the National Library of Administration, 6.8 million people in Canada, or 18% of the total population, were over 65 in 2020. Older people will make up 23% of the population by 2030 when Canada's life expectancy is anticipated to rise from 84.2 to 86.2 years. The market in this region is expected to develop due to the medications' approval and the region's aging population.
The US market dominated the North America Age Related Macular Degeneration (AMD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $4,478.1 million by 2030. The Canada market is experiencing a CAGR of 7.2% during (2023-2030). Additionally, The Mexico market would exhibit a CAGR of 6.3% during (2023-2030).
Based on Drug Type, the market is segmented into Aflibercept, Ranibizumab and Others. Based on Disease Type, the market is segmented into Wet and Dry. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Bayer AG, Apellis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Novartis AG, Sanofi S.A., Coherus Biosciences, Inc. and Bausch Health Companies, Inc.
The most common cause of blindness in senior patients in developed nations is age-related macular degeneration (AMD). It is an eye condition that affects older people's eyes and leads to a progressive loss of the central vision needed for tasks like reading, driving, recognizing people, and examining color. As AMD worsens, many patients lose their ability to read, write, or distinguish between colors and details, which lowers their quality of life. Although the precise functional cause of AMD is not yet fully known, recent advancements in genetic technology have allowed for the identification of several variants that have been found to have distinctive relationships with the disease.
The center of vision becomes blurry as a result. A blood vessel growth abnormality could cause loss of eyesight. On rare occasions, it may be possible to identify abnormal new blood vessels developing from the choroid into the macula. The choroid (sclera), made up of a layer of blood vessels, is located between the retina and the outside, a solid coat of the eye. These abnormal blood vessels may leak blood or fluid, impairing the retina's ability to function.
As the first biosimilar to Lucentis (ranibizumab injection), the U.S. Food and Drug Administration approved Byooviz (ranibizumab-nuna) for the treatment of several eye diseases and conditions, including neovascular (wet) age-related macular degeneration (AMD), a major cause of vision loss and blindness among Americans aged 65 and beyond. Additionally, byooviz is authorized for the treatment of myopic choroidal neovascularization, a risky eye condition brought about by myopia (nearsightedness), as well as macular edema (fluid buildup) following retinal vein occlusion (blockage of veins in the retina). According to the National Library of Administration, 6.8 million people in Canada, or 18% of the total population, were over 65 in 2020. Older people will make up 23% of the population by 2030 when Canada's life expectancy is anticipated to rise from 84.2 to 86.2 years. The market in this region is expected to develop due to the medications' approval and the region's aging population.
The US market dominated the North America Age Related Macular Degeneration (AMD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $4,478.1 million by 2030. The Canada market is experiencing a CAGR of 7.2% during (2023-2030). Additionally, The Mexico market would exhibit a CAGR of 6.3% during (2023-2030).
Based on Drug Type, the market is segmented into Aflibercept, Ranibizumab and Others. Based on Disease Type, the market is segmented into Wet and Dry. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Bayer AG, Apellis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Novartis AG, Sanofi S.A., Coherus Biosciences, Inc. and Bausch Health Companies, Inc.
Scope of the Study
By Drug Type
- Aflibercept
- Ranibizumab
- Others
By Disease Type
- Wet
- Dry
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Biogen, Inc.
- Bayer AG
- Apellis Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals, Inc.
- F.Hoffmann-La Roche Ltd.
- Ionis Pharmaceuticals, Inc.
- Novartis AG
- Sanofi S.A.
- Coherus Biosciences, Inc.
- Bausch Health Companies, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. North America Age Related Macular Degeneration (AMD) Market by Drug Type
Chapter 6. North America Age Related Macular Degeneration (AMD) Market by Disease Type
Chapter 7. North America Age Related Macular Degeneration (AMD) Market by Distribution Channel
Chapter 8. North America Age Related Macular Degeneration (AMD) Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Biogen, Inc.
- Bayer AG
- Apellis Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd.
- Ionis Pharmaceuticals, Inc.
- Novartis AG
- Sanofi S.A.
- Coherus Biosciences, Inc.
- Bausch Health Companies, Inc.
Methodology
LOADING...
